glucagon has been researched along with sr141716 in 3 studies
| Studies (glucagon) | Trials (glucagon) | Recent Studies (post-2010) (glucagon) | Studies (sr141716) | Trials (sr141716) | Recent Studies (post-2010) (sr141716) |
|---|---|---|---|---|---|
| 26,039 | 1,498 | 3,054 | 2,229 | 60 | 631 |
| Protein | Taxonomy | glucagon (IC50) | sr141716 (IC50) |
|---|---|---|---|
| Bile salt export pump | Homo sapiens (human) | 10 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 0.0069 | |
| Cannabinoid receptor 1 | Rattus norvegicus (Norway rat) | 0.0081 | |
| Cannabinoid receptor 1 | Homo sapiens (human) | 0.0219 | |
| Cytochrome P450 2C19 | Homo sapiens (human) | 0.0069 | |
| Cannabinoid receptor 2 | Homo sapiens (human) | 2.4666 | |
| Cannabinoid receptor 1 | Mus musculus (house mouse) | 0.025 | |
| Mu-type opioid receptor | Cavia porcellus (domestic guinea pig) | 0.108 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 3.795 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cani, PD; Delzenne, NM; Lambert, DM; Montoya, ML; Neyrinck, AM | 1 |
| Debaty, I; Halimi, S; Muller, M; Villaret, L | 1 |
| Bahekar, R; Jain, MR; Joharapurkar, AA; Kshirsagar, SG; Patel, KN; Patel, V; Srivastava, BK | 1 |
1 review(s) available for glucagon and sr141716
| Article | Year |
|---|---|
[New therapies for type 2 diabetes: what place for incretin-based agents and rimonabant compared to the previous ones?].
Topics: Administration, Oral; Diabetes Mellitus, Type 2; Glucagon; Glycoside Hydrolase Inhibitors; Humans; Hyperglycemia; Hypoglycemic Agents; Incretins; Metabolic Syndrome; Metformin; Piperidines; Pyrazoles; Rimonabant; Safety; Sulfonylurea Compounds; Thiazolidinediones | 2008 |
2 other study(ies) available for glucagon and sr141716
| Article | Year |
|---|---|
Potential modulation of plasma ghrelin and glucagon-like peptide-1 by anorexigenic cannabinoid compounds, SR141716A (rimonabant) and oleoylethanolamide.
Topics: Animals; Appetite Regulation; Blood Glucose; Blotting, Western; Cannabinoids; Eating; Endocannabinoids; Ghrelin; Glucagon; Glucagon-Like Peptide 1; Male; Oleic Acids; Peptide Fragments; Peptide Hormones; Piperidines; Protein Precursors; Pyrazoles; Rats; Rats, Wistar; Receptors, Drug; Rimonabant | 2004 |
Cannabinoid receptor 1 antagonist treatment induces glucagon release and shows an additive therapeutic effect with GLP-1 agonist in diet-induced obese mice.
Topics: Animals; Anti-Obesity Agents; Blood Glucose; Body Weight; Diet, High-Fat; Drug Synergism; Eating; Exenatide; Glucagon; Glucagon-Like Peptide 1; Insulin Resistance; Male; Mice, Inbred C57BL; Mice, Obese; Obesity; Peptides; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Venoms | 2014 |